Bing

SEARCH HISTORY

Celgene Corporation (NASDAQ: CELG) gained 9.5% to $134.50 after the company announced its plans to acquire Receptos for $7.2 billion and lifted its earnings forecast for 2015. Share volume was 10.2 million, overwhelming an all-day average of 4.4 million
BayStreet · 7/15/2015
Yesterday, Celgene (CELG) reported that it was going to buy Receptos (RCPT) and the stock popped nearly 8% at the open. That big gap ultimately held and the stock closed 6.95% higher. That's a big gap to hold. But I think today is the more important day.
realmoney.thestreet.com · 7/16/2015
At the end of June 2015, the Celgene had roughly $5.1 billion remaining under its stock repurchase program, including its most recent $4.0 billion share repurchase authorization. Bob Hugin, chairman and CEO of Celgene, said: The Celgene team delivered ...
24/7 Wall ST · 7/23/2015
Celgene
Celgene Corporation (CELG) is not your typical biotech stock. While the stock market has been choppy for the last few months and many risk-on plays in biotechnology have seen plenty of volatility, CELG stock has been marching steadily higher since 2013 ...
NASDAQ · 3/23/2015
That’s apparently the case with Celgene (CELG), the biggest gainer in the Standard & Poor’s 500 index Wednesday. Celgene stock is up more than 9% following its announcement late Tuesday that the cancer drug maker is paying $7.32 billion in cash …
USA TODAY MONEY · 7/15/2015
CHICAGO, July 22, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FIT, MNKD, CELG, YHOO and ZU. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
Financial Content · 7/22/2015
Critical Alerts
... with quite a few companies including Kite Pharma and Celgene CELG. bluebird’s position in gene therapy, its technology platform as well as partnerships make this Zacks Rank #2 (Buy) stock an attractive investment option. Another company poised for ...
Yahoo News · 17 hours ago
Biogen
CELG is, in a sense, a biotech ETF of its own… with managers ... Investment implications: Biotechs are legion, and with the industry having experienced years of strong growth and stock appreciation, more new issues are coming. Investors who want to ...
Equities · 20 hours ago
Biotech Stocks
Although shares of biotech blue-chip stock Celgene (NASDAQ: CELG) are relatively unchanged in 2015, shareholders over the past couple of years have been treated to one heck of a ride higher. Over the trailing three-year period, shares are up more than …
Investopedia · 6/22/2015
Celgene Corporation (NASDAQ: CELG) signed a definitive agreement to acquire Receptos (NASDAQ: RCPT) for $232 per share or a total of approximately $7.2 billion. The stock price of Celgene closed $122.85 per …
OppTrends · 7/14/2015
Celgene

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia